Net Income

Sintana Energy's all-share acquisition of Challenger gets final approval, creating a new exploration leader with high-impact assets in Namibia and Uruguay.

Acadia's new powder form of the only Rett syndrome drug offers families vital choice, easing daily care and showing the power of patient-led innovation.

Predictive Oncology rebrands as Axe Compute, betting its future not on algorithms, but on solving the critical shortage of AI compute power. A deep dive.

A Maryland community bank is voluntarily leaving Nasdaq. We analyze why shedding public market burdens is an increasingly popular survival strategy.

Beyond the dividend payout, Cherry Hill Mortgage's strategy reveals a deeper pivot towards digital innovation, balancing high yields with new frontiers of risk.

A new nonprofit telehealth platform for men is launching, but its true innovation may lie in its ambitious blend of holistic care and community support.

With full control of a prized Turkish zinc mine, Pasinex bets big on a 1,000-meter deep dig. Can this capital-intensive play pay off in a shifting market?

As logistics giant Ryder plans a seamless CEO shift from Sanchez to insider John Diez, we analyze the strategy of continuity in a volatile market.

With over 123 million displaced, refugee camps are now de facto cities. Temporary water solutions are fueling disease, making the case for permanent fixes.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

With a €1.5B capital raise backed by governments and strategic giants, Eutelsat is fueling its unique hybrid satellite network to compete in the new space race.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Malaysia's Treasure Global secures fresh capital, but a brutal market reaction and high cash burn raise questions about its super app's future.

A $277M secondary offering sees MIAX shareholders cash in, but the company itself isn't taking any money. Here’s what that says about its financial power.

An independent study shows Mesoblast’s cell therapy has superior remission rates over a market leader, hinting at a new standard of care and a big win for investors.

A new 'inspired by' fragrance brand is betting its vertically integrated model and aggressive pricing can break the industry’s century-old luxury spell.

Centrus Energy is building a key Ohio facility, the first step in a multi-billion dollar plan to end US reliance on Russian uranium for next-gen reactors.

AMC's key governance reforms failed despite 90% voter support, stymied by low turnout. Meanwhile, a major share increase passed. What does this mean?

Erie Indemnity boosts its dividend by 7.1%, but a deeper look reveals a unique and legally challenged fee structure driving its profitability.

Datavault AI is issuing a 'meme coin' to shareholders. Is this the future of corporate rewards or a regulatory tightrope walk with a speculative asset?